EnteroMedics’ Obesity Study Yields Positive Results
EnteroMedics says positive results from its ReCharge study evaluating its vBloc neurometabolic therapy in moderately obese patients with a related comorbid condition have been published in the journal Obesity Surgery.
Patients with vBloc experienced 74 percent greater weight loss compared with a control, with an average loss of 33 percent excess weight at 12 months. Additionally, a third of the patient pool lost at least 20 percent, and a quarter lost at least 50 percent.
No serious adverse events occurred through 12 months, according to the company. — Anisa Jibrell